CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...